These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38912043)

  • 1. VOE: automated analysis of variant epitopes of SARS-CoV-2 for the development of diagnostic tests or vaccines for COVID-19.
    Lee D; Sangket U
    PeerJ; 2024; 12():e17504. PubMed ID: 38912043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico discovery of antigenic proteins and epitopes of SARS-CoV-2 for the development of a vaccine or a diagnostic approach for COVID-19.
    Can H; Köseoğlu AE; Erkunt Alak S; Güvendi M; Döşkaya M; Karakavuk M; Gürüz AY; Ün C
    Sci Rep; 2020 Dec; 10(1):22387. PubMed ID: 33372181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of HLA-A*24:02-Restricted CTL Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 and Analysis of Their Conservation Using the Mutation Database of SARS-CoV-2 Variants.
    Takagi A; Matsui M
    Microbiol Spectr; 2021 Dec; 9(3):e0165921. PubMed ID: 34937174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revelation of Potent Epitopes Present in Unannotated ORF Antigens of SARS-CoV-2 for Epitope-Based Polyvalent Vaccine Design Using Immunoinformatics Approach.
    Uttamrao PP; Sathyaseelan C; Patro LPP; Rathinavelan T
    Front Immunol; 2021; 12():692937. PubMed ID: 34497604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of RT-PCR and antigen-based rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 detection: performance, variant specificity, and clinical implications.
    Aboagye FT; Annison L; Hackman HK; Acquah ME; Ashong Y; Owusu-Frimpong I; Egyam BC; Annison S; Osei-Adjei G; Antwi-Baffour S
    Microbiol Spectr; 2024 Jun; 12(6):e0007324. PubMed ID: 38683014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A, -B, -C) across global populations.
    Cun Y; Li C; Shi L; Sun M; Dai S; Sun L; Shi L; Yao Y
    Hum Vaccin Immunother; 2021 Apr; 17(4):1097-1108. PubMed ID: 33175614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
    Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
    Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T and B cell Epitope analysis of SARS-CoV-2 S protein based on immunoinformatics and experimental research.
    Chen Z; Ruan P; Wang L; Nie X; Ma X; Tan Y
    J Cell Mol Med; 2021 Jan; 25(2):1274-1289. PubMed ID: 33325143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunodominant linear B cell epitopes in the spike and membrane proteins of SARS-CoV-2 identified by immunoinformatics prediction and immunoassay.
    Polyiam K; Phoolcharoen W; Butkhot N; Srisaowakarn C; Thitithanyanont A; Auewarakul P; Hoonsuwan T; Ruengjitchatchawalya M; Mekvichitsaeng P; Roshorm YM
    Sci Rep; 2021 Oct; 11(1):20383. PubMed ID: 34650130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of a Recombinant Multivalent Epitope Vaccine Based on SARS-CoV-2 and Its Variants in Immunoinformatics Approaches.
    Yu M; Zhu Y; Li Y; Chen Z; Li Z; Wang J; Li Z; Zhang F; Ding J
    Front Immunol; 2022; 13():884433. PubMed ID: 35603198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-protection induced by highly conserved human B, CD4
    Prakash S; Dhanushkodi NR; Zayou L; Ibraim IC; Quadiri A; Coulon PG; Tifrea DF; Suzer B; Shaik AM; Chilukuri A; Edwards RA; Singer M; Vahed H; Nesburn AB; Kuppermann BD; Ulmer JB; Gil D; Jones TM; BenMohamed L
    Front Immunol; 2024; 15():1328905. PubMed ID: 38318166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoinformatics prediction of overlapping CD8
    Fatoba AJ; Maharaj L; Adeleke VT; Okpeku M; Adeniyi AA; Adeleke MA
    Vaccine; 2021 Feb; 39(7):1111-1121. PubMed ID: 33478794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Platform for Producing Recombinant Protein Components of Epitope Vaccines for the Prevention of COVID-19.
    Karyagina AS; Gromov AV; Grunina TM; Lyaschuk AM; Grishin AV; Strukova NV; Generalova MS; Galushkina ZM; Soboleva LA; Dobrinina OY; Bolshakova TN; Subbotina ME; Romanovskaya-Romanko EA; Krasilnikov IV; Polyakov NB; Solovyev AI; Grumov DA; Zhukhovitsky VG; Ryabova EI; Prokofiev VV; Lunin VG
    Biochemistry (Mosc); 2021 Oct; 86(10):1275-1287. PubMed ID: 34903153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.
    Dayan GH; Rouphael N; Walsh SR; Chen A; Grunenberg N; Allen M; Antony J; Asante KP; Bhate AS; Beresnev T; Bonaparte MI; Celle M; Ceregido MA; Corey L; Dobrianskyi D; Fu B; Grillet MH; Keshtkar-Jahromi M; Juraska M; Kee JJ; Kibuuka H; Koutsoukos M; Masotti R; Michael NL; Neuzil KM; Reynales H; Robb ML; Villagómez Martínez SM; Sawe F; Schuerman L; Tong T; Treanor J; Wartel TA; Diazgranados CA; Chicz RM; Gurunathan S; Savarino S; Sridhar S;
    Lancet Respir Med; 2023 Nov; 11(11):975-990. PubMed ID: 37716365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoinformatics Approach for the Identification and Characterization of T Cell and B Cell Epitopes towards the Peptide-Based Vaccine against SARS-CoV-2.
    Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Lee SS
    Arch Med Res; 2021 May; 52(4):362-370. PubMed ID: 33546870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies.
    Wang X; Zhao X; Song J; Wu J; Zhu Y; Li M; Cui Y; Chen Y; Yang L; Liu J; Zhu H; Jiang S; Wang P
    Emerg Microbes Infect; 2022 Dec; 11(1):477-481. PubMed ID: 35034583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins.
    Devi YD; Goswami HB; Konwar S; Doley C; Dolley A; Devi A; Chongtham C; Dowerah D; Biswa V; Jamir L; Kumar A; Satapathy SS; Ray SK; Deka RC; Doley R; Mandal M; Das S; Singh CS; Borah PP; Nath P; Namsa ND
    PLoS One; 2021; 16(11):e0258645. PubMed ID: 34780495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.